NVAX Stock Analysis: Buy, Sell, or Hold?
NVAX - Novavax Inc
$7.46
-0.37 (-4.66%)
▼
5d:
-9.14%
30d:
-16.18%
90d:
-8.47%
HOLD
MODERATE Confidence
Analysis Updated: Jul 24, 2026 12:00 AM ET
Earnings: Aug 05, 2026
9d
Smart Money Accumulation
None View Scanner →
Strength: 8.0/10
Get Alerted When NVAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: NVAX shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: NVAX is currently trading at $7.46, which is considered oversold relative to its 30-day fair value range of $8.23 to $9.46. From a valuation perspective, the stock is trading at a discount (Forward PE: -29.3) compared to its historical average (35.1). At these levels, the market is pricing in 0% annual earnings growth.
Technical Outlook: Technically, NVAX is in a uptrend. The price is currently testing key support at $7.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: NVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.11 (+89.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVAX is in a uptrend. The price is currently testing key support at $7.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.7% recently.
Market Sentiment: NVAX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.11 (+89.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$8.23 -
$9.46
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding NVAX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.7%)
- BULLISH: Trading 89.2% below Wall St target ($14.11)
- CAUTION: 5-day price weakness (-9.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$8.23 -
$9.46
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$7.45
Resistance Level
$9.27
Current Trend
Uptrend
Technical data as of
Jul 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-29.31
Wall Street Target
$14.11
(+89.2%)
Revenue Growth (YoY)
-79.1%
Earnings Growth (YoY)
-38.1%
Profit Margin
-14.7%
PE vs Historical
-29.3 vs 35.1
CHEAP
Share & Embed Analysis
Last updated: July 26, 2026 4:43 AM ET
Data refreshes hourly during market hours. Next update: 5:43 AM
Data refreshes hourly during market hours. Next update: 5:43 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$435 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 48 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$56 | 53 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$554 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$125 | 54 HOLD |
Advanced NVAX Option Strategies
Professional options setups generated by AI based on today's NVAX price and gamma walls.
